46 Xy Partial Gonadal Dysgenesis C4510744
A genetic condition where XY individuals have underdeveloped gonads causing atypical genital development and possible hormone deficiencies. Care is individualized, often involving hormone therapy and surgical options.
Key facts at a glance
- ICD-10
- Q55.9
- ICD-11
- LA00.0
- Body system
- reproductive
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Gonadoblastoma
Benign or malignant tumor developing in dysgenic gonads, often calcified and detectable on imaging.
URGENT: Any pelvic pain, palpable mass, or rapid onset of masculine features requires immediate evaluation for possible tumor.
Gonadal tumor risk
Increased lifetime risk of malignant germ cell tumors (including dysgerminoma and seminoma) in streak gonads.
URGENT: Regular screening with ultrasound recommended; report any abdominal/pelvic pain, swelling, or hormonal changes immediately.
Ambiguous genitalia
(reproductive)External genitalia that appear neither clearly male nor clearly female due to incomplete male genital development.
Frequency: 70-80% of patients
Hypospadias
(reproductive)Urethral opening on the underside of the penis instead of the tip, often associated with chordee (curved penis).
Frequency: 60-70% of patients
Cryptorchidism
(reproductive)One or both testes fail to descend into the scrotum, remaining in the abdomen or inguinal canal.
Frequency: 50-60% of patients
Primary amenorrhea
(reproductive)Failure to begin menstruation by age 15 or within 3 years of secondary sexual characteristic development.
Frequency: 40-50% of patients
Delayed puberty
(reproductive)Absence of secondary sexual characteristics (breast development, menstruation in females; testicular enlargement, voice changes in males) by expected age.
Frequency: 40-50% of patients
Primary infertility
(reproductive)Inability to conceive naturally due to gonadal dysfunction and impaired gamete production.
Frequency: 60-70% of patients
Short stature
(constitutional)Height below expected range for age and genetic background, often becoming apparent in childhood.
Frequency: 15-25% of patients
Hypertension
(cardiovascular)Elevated blood pressure, potentially related to renal abnormalities that may accompany gonadal dysgenesis.
Frequency: 10-15% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Hormone Replacement Therapy
Individualized hormone replacement based on assigned gender, phenotypic presentation, and endogenous hormone production to support development and metabolic function.
Endocrine and Oncologic Surveillance
Regular monitoring of hormone levels, bone density, and gonadal tissue for malignancy risk through imaging and tumor markers.
Additional treatment options
Gonadal Management Surgery
Surgical intervention for gonadal tissue management including removal of streak gonads or undescended tissue, and gender-affirming genital reconstruction as indicated.
surgicalPsychological Counseling and Support
Comprehensive psychological support addressing gender identity, body image, and adjustment to diagnosis, with involvement of family when appropriate.
psychologicalHealthy Lifestyle Support
Guidance on nutrition, exercise, and general health maintenance to support bone health, cardiovascular wellness, and psychological well-being.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is 46 Xy Partial Gonadal Dysgenesis C4510744?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Lee PA, Houk CP, Ahmed SF, Hughes IA. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics. 2006;118(2):e488-e500.
Endocrine Society. Endocrine Society position statement: 46,XY disorders of sex development. J Clin Endocrinol Metab. 2008;93(10):ix-x.
Mendoza N, Motohara-Matsuo K, Castro MJ, Nishi MY, Bachega TA, Spinola-Castro AM, Domenice S, Latronico AC, Mendonca BB. 46,XY disorders of sexual development: insights into pathophysiology and treatment. Endocrine. 2023;79(3):491-506.
Miller WL, Achermann JC. Disorders of sex development. In: Melmed S, et al. Williams Textbook of Endocrinology. 14th ed. Elsevier; 2020:901-968.
Ostrer H. Disorders of sex development (DSD): should we change the name to differentiate XY DSD from other DSD? Sex Dev. 2019;13(2):65-73.
Kulle A, Kragesteen L, Sutter C, Holterhus PM. The molecular diagnosis of 46,XY disorders of sex development: experience from a reference center. J Clin Endocrinol Metab. 2022;107(3):785-795.
European Society for Pediatric Endocrinology. ESPE Consensus Guidelines on Disorders of Sex Development. J Pediatr Endocrinol Metab. 2020;33(9):1051-1064.
Hughes IA. Disorders of sex development: a spectrum of presentation. Ann Endocrinol (Paris). 2021;82(3-4):153-157.
Baxter RM, Vilain E. Understanding gonadal dysgenesis in 46,XY individuals: genetic basis and clinical implications. Ann Endocrinol (Paris). 2023;84(2):201-210.
Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, Meyer-Bahlburg HFL, Miller WL, Migeon CJ, New MI. Congenital adrenal hyperplasia due to 46,XY adrenal dysgenesis: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4067.
Medication Comparisons
Compare medications used to treat 46 Xy Partial Gonadal Dysgenesis C4510744. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy